HIF-1 mediated activation of antimicrobial peptide LL-37 in type 2 diabetic patients
dc.contributor.author | Mohanty S. | |
dc.contributor.author | Kamolvit W. | |
dc.contributor.author | Zambrana S. | |
dc.contributor.author | Gonzales E. | |
dc.contributor.author | Tovi J. | |
dc.contributor.author | Brismar K. | |
dc.contributor.author | Östenson C.G. | |
dc.contributor.author | Brauner A. | |
dc.contributor.other | Mahidol University | |
dc.date.accessioned | 2023-06-18T16:51:06Z | |
dc.date.available | 2023-06-18T16:51:06Z | |
dc.date.issued | 2022-01-01 | |
dc.description.abstract | Abstract: Infections are common in patients with diabetes, but increasing antibiotic resistance hampers successful bacterial clearance and calls for alternative treatment strategies. Hypoxia-inducible factor 1 (HIF-1) is known to influence the innate immune defense and could therefore serve as a possible target. However, the impact of high glucose on HIF-1 has received little attention and merits closer investigation. Here, we show that higher levels of proinflammatory cytokines and CAMP, encoding for the antimicrobial peptide cathelicidin, LL-37, correlate with HIF-1 in type 2 diabetic patients. Chemical activation of HIF-1 further enhanced LL-37, IL-1β, and IL-8 in human uroepithelial cells exposed to high glucose. Moreover, HIF-1 activation of transurethrally infected diabetic mice resulted in lower bacterial load. Drugs activating HIF-1 could therefore in the future potentially have a therapeutic role in clearing bacteria in diabetic patients with infections where antibiotic treatment failed. Key messages: • Mohanty et al. “HIF-1 mediated activation of antimicrobial peptide LL-37 in type 2 diabetic patients.” • Our study highlights induction of the antimicrobial peptide, LL-37, and strengthening of the innate immunity through hypoxia-inducible factor 1 (HIF-1) in diabetes. • Our key observations are: 1. HIF-1 activation increased LL-37 expression in human urothelial cells treated with high glucose. In line with that, we demonstrated that patients with type 2 diabetes living at high altitude had increased levels of the LL-37. 2. HIF-1 activation increased IL-1β and IL-8 in human uroepithelial cells treated with high glucose concentration. 3. Pharmacological activation of HIF-1 decreased bacterial load in the urinary bladder of mice with hereditary diabetes. • We conclude that enhancing HIF-1 may along with antibiotics in the future contribute to the treatment in selected patient groups where traditional therapy is not possible. | |
dc.identifier.citation | Journal of Molecular Medicine Vol.100 No.1 (2022) , 101-113 | |
dc.identifier.doi | 10.1007/s00109-021-02134-7 | |
dc.identifier.eissn | 14321440 | |
dc.identifier.issn | 09462716 | |
dc.identifier.pmid | 34651203 | |
dc.identifier.scopus | 2-s2.0-85117052364 | |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/83951 | |
dc.rights.holder | SCOPUS | |
dc.subject | Biochemistry, Genetics and Molecular Biology | |
dc.title | HIF-1 mediated activation of antimicrobial peptide LL-37 in type 2 diabetic patients | |
dc.type | Article | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85117052364&origin=inward | |
oaire.citation.endPage | 113 | |
oaire.citation.issue | 1 | |
oaire.citation.startPage | 101 | |
oaire.citation.title | Journal of Molecular Medicine | |
oaire.citation.volume | 100 | |
oairecerif.author.affiliation | Siriraj Hospital | |
oairecerif.author.affiliation | Universidad Mayor de San Andres Bolivia | |
oairecerif.author.affiliation | Karolinska Universitetssjukhuset | |
oairecerif.author.affiliation | Karolinska Institutet | |
oairecerif.author.affiliation | Capio Health Care Center |